AstraZeneca PLC
AZN.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.47T
Close$
$2972.88
86.8% upside
Current Fair Value
86.8% upsideUndervalued by 86.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.47 Trillion |
|---|---|
| Enterprise Value | $2.50 Trillion |
| Dividend Yield | $29.86 (1.99%) |
| Earnings per Share | $6.6 |
| Beta | 0.21 |
| Outstanding Shares | 1,551,000,000 |
Return
| Return on Equity | 20.79% |
|---|---|
| Return on Assets | 9.03% |
| Return on Invested Capital | 16.92% |
Valuation & Multiples
| P/E Ratio | 23.65 |
|---|---|
| PEG | 1016.63 |
| Price to Sales | 40.81 |
| Price to Book Ratio | 49.73 |
| Enterprise Value to Revenue | 40.67 |
| Enterprise Value to EBIT | 175.16 |
| Enterprise Value to Net Income | 238 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 27, 2026
EPS Estimate
$24.11
Average shareholder expectationRevenue Estimate
$150.30 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$26.21
Average shareholder expectationRevenue Estimate
$157.94 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AstraZeneca Plc
96,100 employees
CEO: Pascal Soriot AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...